Autologous blood transfusion with haematopoietic stem cells
Autologous blood transfusion with haematopoietic stem cells: Transfusion of autologous blood containing haematopoietic stem cells for haematopoietic reconstruction after chemotherapy.Blood tests were performed weekly, if the patient's neutrophils were less than 1.0 × 109 / L during chemotherapy, G-CSF was given as a remedial treatment. If fever occurs, antibiotics were given promptly.Monitor peripheral blood after transfusion. If peripheral blood leukocyte count does not reach 1.0 x 109/L, administer G-CSF 150 μg subcutaneously daily until peripheral blood leukocyte count reaches 1.0 x 109/L.Patients were tested monthly for peripheral blood cells for 6 months after the end of treatment.
Study summary
The aim of this project is to use autologous haematopoietic stem cell transfusion support to promote the reconstruction of haematopoietic function after chemotherapy for ovarian cancer. To explore the impact of stored haematopoietic stem cell support therapy on bone marrow protection after conventional chemotherapy for ovarian cancer in order to facilitate its clinical application.
Eligibility
Sex
FEMALE
Min age
18 Years
Max age
60 Years
Healthy volunteers
No
Inclusion Criteria:
* 18-60 years old;
* there are chemotherapy indicators for ovarian cancer;
* ovarian cancer diagnosed by histopathology;
* recurrent and metastatic ovarian cancer;
* the Eastern Cooperative Oncology Group (ECOG) performance status score≤1;
* the expected survival time was more than 3 months;
* pre-menopausal women (post-menopausal women must have been postmenopausal for at least 12 months to be considered infertile), and the serum pregnancy test results are negative;
* all patients must agree to take effective contraceptive measures during the study period and within 6 months after stopping treatment;
* the subjects voluntarily participate in this clinical trial sign an informed consent form and are able to complete the study procedures and follow-up examinations;
* bone marrow function is good,ability to perform stem cell mobilisation and collection.
Exclusion Criteria:
* patients with bone marrow disease;
* central nervous system or soft meningeal or bone or bone marrow metastases confirmed by imaging or pathology;
* patient has severe cardiac insufficiency;
* previous history of allogeneic stem cell transplantation or organ transplantation;
* patients with active bleeding and autoimmune thrombocytopenic purpura;
* patients with chemotherapy contraindications;
* positive for human immunodeficiency virus (HIV);
* acute or chronic active hepatitis B or hepatitis C infection.
Primary outcome measure(s)
Incidence of Grade 3-4 neutropenia — 8 months Incidence of Grade 3-4 neutropenia
Time to reconstruct haematopoietic function — 6 months Time to reconstruct haematopoietic function
Incidence of febrile neutropenia (FN) — 8 months Incidence of febrile neutropenia (FN)
Trial sites (1)
Facility
City
Region
Status
Chongqing University Cancer Hospital
Chongqing
Chongqing Municipality
Recruiting
More Chongqing University Cancer Hospital trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.